ZymoGenetics, Inc.(NasdaqGM: ZGEN)
rebote en premercado... +83%
Last Trade: 5.30
Trade Time: Sep 7
Change: 0.00 (0.00%)
Prev Close: 5.30
Open: N/A
Bid: 9.33 x 2000
Ask: N/A
1y Target Est: 6.90
Day's Range: N/A - N/A
52wk Range: 3.70 - 7.31
Volume: 0
Avg Vol (3m): 385,512
Bristol-Myers Squibb Company (BMS) has signed a definitive agreement to acquire ZymoGenetics, a biopharmaceutical company focused on the development and commercialisation of therapeutic proteins.
With the acquisition of ZymoGenetics, BMS is expected to get full ownership of pegylated-interferon lambda, Recothrom, IL-21 protein and an earlier-stage pipeline of six biologic drug candidates, including an anti-IL-31 antibody, currently in pre-clinical development for atopic dermatitis.
Pegylated-interferon lambda is a new interferon in Phase IIb development for the treatment of Hepatitis C infection.
Recothrom is a recombinant thrombin approved by the US Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures.
IL-21 protein is a cytokine currently being tested in an open-label, Phase II clinical study as a potential immunotherapy treatment for metastatic melanoma.
Additionally, BMS also gets potential milestone and royalty payments from six partnered programs in various stages of clinical development by EMD Serono, an affiliate of Merck KGaA, and Novo Nordisk.
BMS CEO Lamberto Andreotti said that the acquisition of ZymoGenetics brings them- full ownership of a promising investigational biologic that strengthens their diversified Hepatitis C portfolio.
“In addition, ZymoGenetics brings proven capabilities with therapeutic proteins and revenue from a marketed specialty surgical biologic,†Andreotti said.
ZymoGenetics CEO Douglas Williams said that by joining forces with BMS, they believe that they would enhance the long-term potential of ZymoGenetics’ portfolio of assets, while providing a compelling valuation for their shareholders.
BMS executive vice president and CEO Elliott Sigal said that they expect ZymoGenetics’ pipeline and biologics capabilities to complement and enhance their existing efforts in Hepatitis C, oncology and immunoscience.
